Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $115.00 short put and a strike $105.00 long put offers a potential 11.73% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $1.05 would be kept by the premium seller. The risk of $8.95 would be incurred if the stock dropped below the $105.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 73.91 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Allegiance Corporation — Moody's affirms Cardinal Health's Baa2 senior unsecured rating; outlook changed to negative
Fri, 17 Jan 2020 20:51:11 +0000
Rating Action: Moody's affirms Cardinal Health's Baa2 senior unsecured rating; outlook changed to negative. Global Credit Research- 17 Jan 2020. New York, January 17, 2020– Moody's Investors Service affirmed …
Boston Scientific Gets a Boost From New Products, Buyouts
Fri, 17 Jan 2020 13:42:01 +0000
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
Fri, 17 Jan 2020 13:27:01 +0000
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
Fri, 17 Jan 2020 12:10:12 +0000
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show
Thu, 16 Jan 2020 15:01:03 +0000
NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Also on Market Tamer…
Follow Us on Facebook